中國體外診斷 (IVD) 市場分析:未來預測 (至2023年)
Chinese In-vitro Diagnostics Market Insight, Forecast to 2023
|出版商||Frost & Sullivan||商品編碼||877674|
|出版日期||內容資訊||英文 65 Pages
|中國體外診斷 (IVD) 市場分析:未來預測 (至2023年) Chinese In-vitro Diagnostics Market Insight, Forecast to 2023|
|出版日期: 2019年06月21日||內容資訊: 英文 65 Pages||
中國體外診斷 (IVD) 市場規模受到人口高齡化與可用所得上升、醫療制度改革等因素影響、預計今後將更進一步的擴大。另外、市場也開始二極化、高端產品由外資企業獨佔、國內企業預計將持續依賴低價產品。
本報告針對中國國內體外診斷 (IVD) 市場分析、提供市場全體構造與促進、阻礙因素、全體市場動向預測 (今後5年份)、種類分類 (免疫化學、分子診斷、POCT) 詳細動向、主要企業市場佔有率構造、今後成長機會方向、規模等調查。
The China Manufacturing 2025 Program for Promoting Local R&D Investments and Increasing Demand from Tier I and II Hospitals Set to Transform the Industry Landscape
The In-vitro Diagnostics (IVD) market in China shows strong growth potential in several segments. Market growth is set to be driven by the growing volume of tests, rather than the higher price of testing solutions in traditional segments and the popularization of advanced testing technology in emerging segments. In the context of the reform in public hospitals, the IVD industry is the direct beneficiary of the drug price policy and is expected to acquire strong growth potential in the long run. On the supply side, foreign companies are dominating the high-end market by leveraging their technical advantage to develop closed-end systems for their automatic analyzers. However, owing to their lack of input on distribution channels and their high-priced products, they are likely to find it difficult to penetrate the lower-end hospitals in the short term.
The IVD market in China presents a diversified growth potential for the different tiers of competitors: domestic participants gain from the growth momentum for the low-end market, whereas leading foreign manufacturers dominate the high-end market, which is expected to become the new emerging market along with ever-improving localized services to meet various demands. The mid-to-low-end market is crowded with local participants, leading to fierce competition.
China is currently facing severe shortage of anatomic pathologists, which blocks patients' access to quality care. The relatively small number of pathologists are often overworked. Moreover, the penetration of IVD devices has been on the lower side. China has not yet issued a regulation on management standards for independent clinical laboratories. This leads to each laboratory developing its own standards that are not uniform and providing a narrow scope of services (which is not in line with accepted clinical laboratory standards). Overall, the substitution devices developed by local companies are the most important factor in increasing the IVD market size, as it improves the accessibility of lower-end hospitals to advanced IVD technologies, boosting their need to update IVD products.